Human Papilloma Virus Infection Clinical Trial
— ELIMVLHPVOfficial title:
Effects of Estrogen-like Chinese Medicine and Vaginal Lactobacillus on HPV Clearance and Vaginal Microbiota Change in Women With Persistent HPV Infection
High risk human papillomavirus (hr-HPV) persistent infection is a high risk factor for cervical cancer. 85% to 90% of hr-HPV infections have the ability to clear on their own, while 10% to 15% of HPV persists further will lead to the development of high-grade intraepithelial lesions (HSIL) and even to invasive cervical cancer. Long-term follow-up results for persistent hr-HPV infection showed that cervical HSIL mostly occurred after 5-7 years of persistent hr-HPV infection, among which the risk of HPV16 and 18 was the highest, followed by HPV31 and 33. The role of the vaginal microbiome (CVM) in persistent hr-HPV infection has been increasingly valued, and women with persistent HPV infection that progresses to HSIL have a more unstable vaginal microenvironment. The previous study found that Lactobacillus vaginalis may contribute to HPV clearance by improving the vaginal microenvironment. In addition, previous studies have found that estrogen-like Chinese medicine could increase glycogen, improve mucosal estrogen levels, increase lactobacillus content, and promote HPV clearance. It is a challenge to make clinical management on when and how to intervene among hr-HPV persistent infection but whose pathology does not suggest HSIL. This study intends to analyze the correlation between the duration of HPV infection and the current vaginal microbiome, HPV load and PAX1 methylation in people with persistent HPV infection at different ages, and observe the changes of the above indicators after the administration of drugs to improve the vaginal microenvironment, which is helpful for preventing HPV persistent infection and developing into true precancerous lesions. It has the clinical and practical value of "preparing for a rainy day".
Status | Recruiting |
Enrollment | 240 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 25 Years and older |
Eligibility | Inclusion Criteria: - Women over 25 years of age with the same type of high-risk HPV infection lasting for more than 1 year, atypical squamous cell (ASCUS) or Low-grade squamous intraepithelial disease (LSIL) cytologically negative or undiagnosable, and pathological biopsy results negative or LSIL - Consent to use the device for contraception during the study period; - agree with medicine and follow-up management procedure. Exclusion Criteria: - High cytological risk, including atypical squamous cells (ASC-H),HSIL and atypical glandular cell (AGC), which could not rule out high-grade squamous intraepithelial lesions; - pathological biopsy for HSIL and above; - for any drug allergies; - pregnancy or lactation |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | community state type (CST) | Vaginal microflora type | Change of CST at 6 months and 12 months after medication | |
Primary | HPV VL | HPV viral load | Change of HPV VL at 6 months and 12 months after medication | |
Primary | PAX1 methylation test | Pairing box gene1 methylation test | Change of PAX1 methylation test at 6 months and 12 months after medication | |
Secondary | Complete remission (CR) | HPV subtypes with persistent infection turned negative at 6 and 12 months or positive at 6 months, and negative at 12 months | Change of CR at 6 months and 12 months after medication | |
Secondary | Partial remission (PR) | Partial response (PR) : HPV subtypes with persistent infection turned negative at 6 months and returned positive at 12 months | Change of PR at 6 months and 12 months after medication | |
Secondary | No response (NR) | HPV subtypes with persistent infection were positive at both follow-up visits | Change of NR at 6 months and 12 months after medication |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02258659 -
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT02714114 -
Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)
|
N/A | |
Completed |
NCT00303823 -
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
|
Phase 2 | |
Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
Not yet recruiting |
NCT06123533 -
Understanding Women's Values in Managing Human Papillomavirus (HPV)
|
||
Completed |
NCT04624568 -
Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance
|
N/A | |
Completed |
NCT05694728 -
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
|
Phase 2 | |
Completed |
NCT04391647 -
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
|
||
Recruiting |
NCT05439083 -
Immunogenicity of 9-valent HPV Vaccine
|
Phase 4 | |
Completed |
NCT01539668 -
Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas
|
Phase 0 | |
Completed |
NCT01446198 -
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHERâ„¢ System
|
N/A | |
Completed |
NCT01567813 -
Post-Licensure Study of the Safety of GARDASILâ„¢ in Males (V501-070)
|
||
Completed |
NCT02811367 -
The HPV Self-test as a Test of Cure in Madagascar
|
N/A | |
Completed |
NCT02067507 -
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
|
N/A | |
Recruiting |
NCT01387997 -
e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses
|
N/A | |
Completed |
NCT02634190 -
Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
|
||
Completed |
NCT00054041 -
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
|
Phase 2 |